Eli Lilly Triple-G Drug Outperforms Ozempic in Early Diabetes Trial
Eli Lilly has announced new clinical trial results showing that the highest dose of its experimental drug retatrutide surpassed Novo Nordisk’s established diabetes medication Ozempic in reducing blood sugar levels and promoting weight loss. The findings come from a clinical study evaluating the investigational compound.
Trial Findings on Blood Sugar and Weight Loss
According to the company data, participants receiving the maximum dose of retatrutide experienced greater reductions in hemoglobin A1c, a standard measure of long-term blood sugar control, compared to those treated with Ozempic, also known as semaglutide. Additionally, patients on the highest dose of the Eli Lilly therapy achieved greater average weight loss over the course of the study.
Side Effects and Treatment Discontinuations
Despite the promising efficacy metrics, the trial also revealed notable tolerability challenges. Investigators reported that the highest dose of retatrutide was associated with a higher frequency of adverse events and a greater rate of treatment discontinuations among participants compared to the Ozempic control group. These side effects highlight the ongoing clinical challenge of balancing potency against patient tolerability in the development of metabolic therapies.
Context and Regulatory Status
Retatrutide is often referred to as a triple-G agonist because it targets three different hormone receptors involved in metabolic regulation. However, the treatment remains investigational and has not yet received regulatory approval from the Food and Drug Administration or other health authorities. Further clinical studies are required to fully establish the long-term safety, efficacy, and risk-benefit profile of retatrutide before it can become widely available to patients managing type 2 diabetes.
- Retatrutide evaluated against semaglutide in clinical trial
- Higher dose showed greater reductions in blood sugar and body weight
- Increased adverse events and discontinuation rates observed at maximum dose
